Literature DB >> 11711498

Angiotensin II via activation of type 1 receptor upregulates expression of endoglin in human coronary artery endothelial cells.

D Li1, H Chen, J L Mehta.   

Abstract

Transforming growth factor-beta1 and its subtype receptor endoglin are key components in angiogenesis. We explored the role of angiotensin (Ang) II in the expression of endoglin and the underlying intracellular signaling mechanism in human coronary artery endothelial cells. Incubation of cells with Ang II upregulated endoglin expression in a concentration- and time-dependent manner (maximal effect with 10(-6) mol/L Ang II at 24 hours). The Ang II type 1 receptor blocker losartan, but not the type 2 receptor blocker PD 123,319, completely blocked the effect of Ang II. In parallel experiments, the mitogen-activated protein kinase inhibitor PD 098,059 fully inhibited the effect of Ang II on the expression of endoglin. Incubation of endothelial cells with Ang II also increased the expression of transforming growth factor-beta1 and -beta2 receptors and simultaneously decreased the levels of transforming growth factor-beta1. These effects of Ang II were also attenuated by losartan. We propose that Ang II via its type 1 receptor activation modulates the expression of transforming growth factor-beta1 receptors in human coronary endothelial cells. The activation of mitogen-activated protein kinase plays an important role in this process. These observations provide a new clue regarding the regulatory effect of Ang II on vascular remodeling after injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711498     DOI: 10.1161/hy1101.092971

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools.

Authors:  Kristen A Wieghaus; Erwin P Gianchandani; Milton L Brown; Jason A Papin; Edward A Botchwey
Journal:  Tissue Eng       Date:  2007-10

2.  Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.

Authors:  Rudolf A de Boer; Saraswati Pokharel; Markus Flesch; Derk A van Kampen; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst; Dirk J van Veldhuisen; Yigal M Pinto
Journal:  J Mol Med (Berl)       Date:  2004-08-20       Impact factor: 4.599

3.  Cellular basis of diabetic nephropathy: V. Endoglin expression levels and diabetic nephropathy risk in patients with Type 1 diabetes.

Authors:  Patricia Alvarez-Muñoz; Michael Mauer; Youngki Kim; Stephen S Rich; Michael E Miller; Gregory B Russell; José M Lopez-Novoa; M Luiza Caramori
Journal:  J Diabetes Complications       Date:  2009-04-23       Impact factor: 2.852

4.  Circulating endoglin concentration is not elevated in chronic kidney disease.

Authors:  David M Charytan; Alexander M Helfand; Brian A MacDonald; Angeles Cinelli; Raghu Kalluri; Elisabeth M Zeisberg
Journal:  PLoS One       Date:  2011-08-19       Impact factor: 3.240

5.  Suppressive effect of epigallocatechin-3-O-gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo.

Authors:  Chiu-Mei Lin; Hang Chang; Bao-Wei Wang; Kou-Gi Shyu
Journal:  J Cell Mol Med       Date:  2016-06-16       Impact factor: 5.310

6.  Transforming Growth Factor-Beta 1 and Endoglin Levels in Congenital Solitary Functioning Kidney.

Authors:  Nuran Cetın; Nadide Melike Sav; Zeynep Kusku Kıraz; Aylin Gencler
Journal:  Indian J Nephrol       Date:  2020-02-11

Review 7.  Endoglin: a critical mediator of cardiovascular health.

Authors:  Navin K Kapur; Kevin J Morine; Michelle Letarte
Journal:  Vasc Health Risk Manag       Date:  2013-05-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.